Dr. Oz: 1 in 3 Americans leave pharmacy empty-handed over drug costs
This story raises questions about governance, accountability, and American values.
One in three people walking up to a pharmacy counter and walking away without their medicine. Sit with that number for a second. That's not a statistic about healthcare policy in the abstract, that's somebody's blood pressure pills, somebody's insulin, somebody's kid's inhaler, left on the counter because the price tag didn't match the wallet.
New Republican Times Editorial Board

Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz touted the Trump administration’s efforts to lower prescription drug prices, arguing that Americans are beginning to see the impact of the administration’s most-favored-nation pricing agreements and the TrumpRx platform. “This is just what the doctor ordered.
This is the No. 1 issue that Americans fear […]
Original source:
Read at Washington ExaminerHow We See It
New Republican Times Editorial Board
One in three people walking up to a pharmacy counter and walking away without their medicine. Sit with that number for a second. That's not a statistic about healthcare policy in the abstract, that's somebody's blood pressure pills, somebody's insulin, somebody's kid's inhaler, left on the counter because the price tag didn't match the wallet. Dr. Oz putting that figure front and center is the kind of blunt, uncomfortable honesty this issue has needed for years.
What's notable here isn't just the number, it's the framing. Most-favored-nation pricing and TrumpRx aren't slogans, they're an actual attempt to stop Americans from subsidizing cheaper drug prices for Europe while getting soaked at home. That imbalance has been an open secret in Washington for decades, and both parties have talked about fixing it while doing basically nothing. The fact that someone is finally trying to close that gap, and pointing to real movement rather than just promising future relief, is worth taking seriously instead of dismissing as political theater.
Skeptics will say talk is cheap and administrations always claim credit before the results are in. Fair enough, that's a healthy instinct. But the test isn't whether Oz gave a good soundbite, it's whether that one-in-three number starts shrinking in the next round of surveys. If TrumpRx and these pricing deals actually get more people out of the pharmacy with the bag in hand instead of empty-handed, that's the kind of win people feel in their daily lives, not just in a press release. That's the bar, and it's the right one.
Commentary written with AI assistance by the New Republican Times Editorial Board.

